HIV associated with worse outcomes from hospitalised COVID-19 in UK

European and UK doctors review latest studies on HIV and COVID-19 coinfection

Conference opening and making sense of the science

HepC drugs for COVID-19: sofosbuvir/daclatasvir show faster recovery and reduced mortality

Predictors of response to remdesivir in GS-5773 COVID-19 study

Pneumocystis Jirovecii Pneumonia (PJP) mistaken for COVID-19 in late stage undiagnosed: urgency of including HIV testing on admission

NYC cohort reports similar outcomes from COVID-19 in HIV positive vs HIV negative adults

Spanish study reports associations between COVID-19 and HIV treatment including NRTIs

UK study reports inhaled interferon-Beta reduces time to recovery from COVID-19

Review of COVID-19 in people with immune suppression

EMA grants conditional approval for remdesivir in the EU to treat COVID-19

Drug price announced for remdesivir – as US buys up world stock

RECOVERY study reports that lopinavir/r fails to show benefit against COVID-19

Hydroxychloroquine and lopinavir/r arms stopped in the WHO SOLIDARITY study

Individualising management of COVID-19 based on real-time inflammatory responses

Further positive reports from tocilizumab to treat COVID-19

Higher mortality from COVID-19 in London study in Asian or Black compared to white participants

UK study reports antibody responses linked to more severe COVID-19 in higher risk populations

Leading SARS-CoV-2 antibody tests meet specificity but fail current sensitivity guidelines

Infectious SARS-CoV-2 in air and on surfaces in London hospitals

US prisoners have higher mortality rates from COVID-19

US SARS-CoV-2 epidemic could see 100,000 cases per day: NIAID head Anthony Fauci to Senate hearing

Research during COVID-19

Vaccine candidates report phase 3 studies after early safety and immune responses in phase 1/2 studies

FDA guidance on COVID-19 vaccine includes minimal target of 50% efficacy

Latest studies on HIV/COVID-19 coinfection

HIV positive people in South Africa at increased risk of dying from COVID-19: first data from country with high prevalence of HIV and TB

Update on Western Cape data: people with HIV have small increased risks from COVID-19

Dexamethasone significantly reduces mortality in subset of patients hospitalised with advanced COVID-19: UK RECOVERY study

Modelling paper suggests hydroxychloroquine dosing was too low to be active against COVID-19 and that higher doses would risk toxicity

FDA contraindication for remdesivir and hydroxychloroquine (HCQ): immediate impact on current HCQ research

UK RECOVERY study stops hydroxychloroquine (HCQ) for COVID-19: more than 1100 deaths question ethics and safety overall

SIMPLE study reports benefit from 5-day but not 10-day remdesivir on moderate COVID-19

Recent papers on convalescent plasma and on ACE inhibitors and angiotensin receptor blockers

BHIVA/THT updated guidelines for social distancing in the UK

Two PEP studies report no benefit of hydroxychloroquine for preventing CoV-2 infection

COVID-19 harm reduction programmes in Central and Eastern Europe and Central Asia

HIV and COVID-19 coinfection: case reports, retrospective cohorts and outcomes

UK access to remdesivir approved: but MHRA criteria exclude some who could benefit

EMA recommends expanding access to remdesivir

Remdesivir improves recovery time in early COVID-19 infection: first definitive results of benefit

Convalescent plasma therapy for COVID-19

Treatment with interferon in early COVID-19

Famotidine associated with improved clinical outcomes in people hospitalised with COVID-19

Tocilizumab and remdesivir in new dual therapy study

RETRACTED – Re: No benefit from hydroxychloroquine, with or without macrolide antibiotics in analysis of 96,000 patients

BHIVA advice for HIV positive people hospitalised with COVID-19

Changes in taste and smell as symptoms of COVID-19

BHIVA guidelines on shielding: advice for HIV clinicians, GPs and people living with HIV

European consensus on HIV and COVID-19: UK (BHIVA), European (EACS), Spanish, German and Polish HIV organisations

UK guidelines for the treatment of COVID-19: UK prioritises 42 studies

Low CD4s and CD8s – but not viral genetics – predict COVID-19 progression

Autopsies show how COVID-19 damages lungs more than flu

Featured HIV and COVID-19: issue 3 (14 May 2020)

Higher rates of serious outcomes in HIV and COVID-19 coinfection in Germany: cautious review

HIV is not linked to higher risk of COVID-19 in large New York cohort

Case-studies show darunavir does not protect against CoV-2

COVID-19 could lead to 500,000 excess HIV-related deaths in sub-Saharan Africa linked to interruptions in ART supply

Remdesivir for COVID-19: randomised study shows similar antiviral effect to placebo

Other remdesivir news: top results from NIH and Gilead studies – emergency approval in US and Japan

Potential for tocilizumab to treat moderate to severe COVID-19

Detectable viral load and IL-6: a role for tocilizumab or anti-JAK inhibitor baricitinib?

Rheumatoid arthritis drug anakinra in small study to treat COVID-19

Anticoagulants associated with improved survival rates in people hospitalised with COVID-19

Monoclonal antibodies identified in convalescent plasma COVID-19

Post navigation